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Methods: Atherectomy probes from 17 patients with coronary ISR (n=10; time post
stenting 5±3 months) and with peripheral ISR (n=7; 7±3 months) versus those from 10
patients with primary lesions were immunohistochemically examined for the presence of
the determinants CD34, AC133, S100, GFAP, NSE, NGFR and α-smooth muscle (SM)
actin followed by computer-assisted morphometry.
Results: ISR probes demonstrated pronounced hypercellularity (942±318 cells/mm2)
compared to primary lesions (347±120 cells/mm2, P<0.001). α-SM actin positive cells
occupied 67% of intimal cells in ISR. Expression of endothelial progenitor cells (EPCs;
CD34: 7.1±2.5% positive/total cells vs. 0.6±0.7%, P<0.001; AC133: 7.0±3.4% vs.
1.0±0.7%, P<0.001), dendritic cells (DCs; S100: 9.8±5.6% vs. 1.4±1.1%, P<0.001) and
neural-crest derived cells (NCCs; GFAP: 7.9±2.4% vs. 3.1±1.0%; NSE: 4.4±2.6% vs.
1.3±1.6%; NGFR: 4.2±2.5% vs. 1.1±0.7%; each P<0.001) was significantly increased in
ISR compared to primary lesions. Importantly, double immunostaining did not demon-
strate α-SM actin positive cells exhibiting markers of EPCs, DCs or NCCs. With respect
to EPC immunolabelling, AC133 could be detected in a subset of CD34 positive cells,
whereas all cells stained by AC133 also expressed the CD34 antigen. Quantitatively,
both EPC marker proteins revealed a significant correlation (r=0.57, P<0.01). Consis-
tently, there were a only few cells found in ISR atherectomy probes that demonstrated
coexpression of EPC, DC or NCC markers. Our data show residual 5-15% yet unidenti-
fied neointimal cells, that were not stained by any specific cell type marker used.
Conclusions: Bone-marrow and neural-crest derived cells, the most dendritic cells, are
consistently found in ISR, whereas α-SM actin positive cells constitute the largest intimal
cell pool. These data clearly indicate the presence of primarily extravascular cells in
human ISR.
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Aims Inflammatory markers may serve as an important prognostic predictor in patients
with coronary heart diseases. In patients undergoing coronary interventions, it has been
shown that baseline C-reactive protein (CRP) could predict late adverse cardiac events
(clinical restenosis). However, only a few small studies have examined the relation with
angiographic restenosis. In a large number of patients, we examined whether baseline
plasma levels of CRP and IL-6 may predict late coronary angiographic restenosis after
elective coronary stenting.
Methods Pre-procedural plasma levels of CRP and IL-6 were measured in 216 patients
with stable angina pectoris undergoing elective coronary stenting who were included in
the MedStent and DISTINCT trials. Angiographic follow-up was performed in all patients
at 6 months. Angiographic restenosis was defined as diameter stenosis >50% by QCA at
6 months.
Results Baseline CRP levels were 6.45±0.78 mg/L versus 5.24±1.16 mg/L in the patent
and restenosis groups, respectively (p=0.64). IL-6 levels were 0.46±0.03 ng/L versus
0.40±0.07 ng/L in the patent and restenosis groups, respectively (p=0.50). CRP levels
were obtained again at the time of angiographic follow-up and were found to be similar in
both groups (2.89±0.29 mg/L versus 2.61±0.63 mg/L, p=0.72). Moreover, in a sub-group
of 43 patients, serial blood samples were obtained at several time points after the proce-
dure up to 6 months. Both CRP and IL-6 plasma levels were increased significantly in
response to the procedure. CRP levels peaked at 3 days (11.27±1.53 mg/L versus
4.26±0.72 mg/L at baseline, p<0.001). IL-6 levels reached maximum values after 24
hours (1.08±0.14 ng/L versus 0.53±0.08 ng/L at baseline, p<0.001). However, in this sub-
group of patients, neither peak CRP nor IL-6 levels were found to predict late angio-
graphic restenosis.
Conclusion Coronary stenting is associated with transient increases in both CRP and
IL-6 levels. However, pre-procedural CRP and IL-6 levels do not predict late coronary
angiographic restenosis.
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Background: Elevated levels of plasma homocysteine have been associated with athero-
thrombotic diseases.Two polymorphisms, 677C/T and 1298A/C, of methylenetetrahydro-
folate reductase (MTHFR) interfere with enzyme activity and, therefore, may influence
homocysteine levels. We examined the possibility that elevated homocysteine and the
polymorphisms of MTHFR are associated with restenosis and adverse clinical outcomes
after stenting in coronary arteries.
Methods: The study population consisted of 800 patients with symptomatic coronary
artery disease who were treated with stent implantation. Angiographic restenosis (50%
or greater diameter stenosis at 6-month follow-up) and clinical restenosis (need for target
vessel revascularization during the first year after stenting) were evaluated.
Results: Six-month follow-up angiography was done in 601 patients (75.1%). The rates of
angiographic or clinical restenosis were not significantly different between patients with
low or high homocysteine levels or among the genotypes of the MTHFR polymorphisms
(Table). Late lumen loss and loss index were not associated with homocysteine levels or
the MTHFR genotypes (Table). The one-year incidence of death or MI was not depen-
dent on homocysteine concentrations or the genotypes (Table).
Conclusions: Our results suggest that elevated homocysteine levels or the MTHFR poly-
morphisms 677C/T and 1298A/C are not associated with restenosis and adverse clinical
outcomes after stenting in coronary arteries.
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Background: Several lines of evidence suggest that activation of peroxisome prolifera-
tor-activated receptor gamma (PPARγ) may interfere with restenosis. Polymorphisms of
the PPARγ gene were found to be associated with coronary artery disease and diabetes.
We examined the role of the 34C/G and 1431C/T polymorphisms of the PPARγ gene in
restenosis after stenting in patients with diabetes.
Methods: The study population consisted of 752 diabetic patients with symptomatic cor-
onary artery disease who were treated with stenting. Restenosis was defined as a 50%
or greater diameter stenosis six months after the intervention. Clinical outcome mea-
sures (death, myocardial infarction, restenosis-driven reintervention) were evaluated dur-
ing the first year after the intervention. For analysis, patients homozygous for the
common allele were compared with the carriers of the rare allele.
Results: Restenosis rates and continuous measures of restenosis (late lumen loss, loss
index) were not significantly different between the PPARγ genotype groups (Table). In
addition, the one-year incidences of death or myocardial infarction and reintervention
were not significantly different between the groups (Table).
Conclusions: Our results suggest that the PPARγ gene polymorphisms 34C/G and
1431C/T are not associated with restenosis and adverse clinical outcomes after coronary
artery stenting in diabetic patients.
1121-51 SU11218, a Platelet-Derived Growth Factor Receptor 
and Vascular Endothelial Growth Factor Receptor 2 
Inhibitor Blocks Adventitial Angiogenesis and Prevents 
Intimal Hyperplasia After Coronary Stenting in a Porcine 
Model
Asim N. Cheema, Tony S. Hong, Jennifer Dietrich, David Holdsworth, Ken Lipson, 
Bradley H. Strauss, St. Michael's Hospital, Toronto, ON, Canada, John P. Robarts 
Research Institute, London, ON, Canada
Background: Balloon angioplasty has been shown to produce an angiogenic response in
the arterial adventitia, which is associated with restenosis in the injured segment. We
hypothesized that stenting will result in a similar but more prominent adventitial angio-
genic response and inhibition of this angiogenic response with a tyrosine kinase inhibitor
will prevent intimal hyperplasia and restenosis after coronary stenting.
Methods: We performed coronary stenting of the left circumflex artery in 20 Yorkshire
pigs. Pigs were treated with placebo or SU11218, a tyrosine kinase receptor inhibitor that
blocks the activity of PDGFR and VEGFR2, which was administered subcutaneously (5
mg/kg) twice weekly for four weeks. Intravascular ultrasound was performed immediately
after stenting and at four weeks for determination of lumen and intimal cross sectional
areas. Adventitial microvessels were assessed ex vivo in the stented segments by micro-
scopic computed tomography at a resolution of 16 um.
Results: The mean plasma levels for SU 11218 were 1.9-5.8ng/ml. At 4 weeks, arterial
stenting resulted in a marked angiogenic response in vascular adventitia and the number
of adventitial microvessels strongly correlated with the amount of instent intimal hyperpla-
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Angiographic restenosis 
rate (%)
26.0 23.5 26.9 0.75 24.4 25.9 24.0 0.90
Clinical restenosis rate 
(%)
19.5 17.1 23.3 0.37 17.6 18.6 24.7 0.27
Late lumen loss (mm) 1.01 1.04 1.05 0.79 1.02 1.05 0.98 0.69
Loss index 0.60 0.65 0.63 0.71 0.63 0.61 0.68 0.70
Death or MI, 1y (%) 3.2 3.0 6.7 0.22 3.5 3.9 2.1 0.69
Angiographic and clinical outcomes after coronary stenting according to the 
PPARgamma polymorphisms
34CC 34CG + 
34GG
P 
value
1431CC 1431CT + 
1431TT
P 
value
Restenosis rate (%) 35.4 36.2 0.88 35.4 36.3 0.85
Late lumen loss (mm) 1.22 1.30 0.34 1.23 1.24 0.89
Loss index 0.43 0.44 0.74 0.43 0.44 0.80
Death or myocardial 
infarction, 1y (%)
8.3 8.6 0.89 8.0 9.7 0.46
Restenosis-driven 
reintervention, 1y (%)
16.6 14.9 0.60 16.8 14.5 0.47
